144 related articles for article (PubMed ID: 1992987)
1. Ring neutrophils in plasma cell dyscrasia.
Kanoh T
Arch Pathol Lab Med; 1991 Feb; 115(2):178-80. PubMed ID: 1992987
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma arising from monoclonal gammopathy of undetermined significance in a patient with Gaucher's disease.
Brady K; Corash L; Bhargava V
Arch Pathol Lab Med; 1997 Oct; 121(10):1108-11. PubMed ID: 9341594
[TBL] [Abstract][Full Text] [Related]
3. Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients.
Zdzisińska B; Wejksza K; Walter-Croneck A; Turski WA; Kandefer-Szerszeń M
Leuk Res; 2010 Jan; 34(1):38-45. PubMed ID: 19596432
[TBL] [Abstract][Full Text] [Related]
4. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
Bataille R; Jourdan M; Zhang XG; Klein B
J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance: a morphologic and immunophenotypic study of the bone marrow.
Feiner HD; Bannan M; Marsh E; Chuba JV; Espiritu E; Gottesman SR
Mod Pathol; 1992 Jul; 5(4):372-9. PubMed ID: 1495943
[TBL] [Abstract][Full Text] [Related]
7. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies.
Lima M; Teixeira Mdos A; Fonseca S; Gonçalves C; Guerra M; Queirós ML; Santos AH; Coutinho A; Pinho L; Marques L; Cunha M; Ribeiro P; Xavier L; Vieira H; Pinto P; Justiça B
Blood Cells Mol Dis; 2000 Dec; 26(6):634-45. PubMed ID: 11358356
[TBL] [Abstract][Full Text] [Related]
10. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
Jánosi J; Sebestyén A; Mikala G; Németh J; Kiss Z; Vályi-Nagy I
Haematologica; 2004 Mar; 89(3):370-1. PubMed ID: 15020284
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
12. The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Horak P; Minarik J
Haematologica; 2005 Dec; 90(12):1713-4. PubMed ID: 16330455
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
14. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Rajkumar SV; Lacy MQ; Kyle RA
Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
[TBL] [Abstract][Full Text] [Related]
16. Biclonal gammopathy in multiple myeloma: a case report.
Bakta IM; Sutarka IN
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():544-8. PubMed ID: 10895208
[TBL] [Abstract][Full Text] [Related]
17. CD28, a marker associated with tumoral expansion in multiple myeloma.
Robillard N; Jego G; Pellat-Deceunynck C; Pineau D; Puthier D; Mellerin MP; Barillé S; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Clin Cancer Res; 1998 Jun; 4(6):1521-6. PubMed ID: 9626472
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal gammopathies: differential diagnosis with bone marrow biopsy].
Faravelli A; Ponzoni M; Zoldan MC; Ricci D; Camba L
Pathologica; 1994 Jun; 86(3):258-66. PubMed ID: 7808796
[TBL] [Abstract][Full Text] [Related]
19. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
[TBL] [Abstract][Full Text] [Related]
20. New insights in the clinical biology of multiple myeloma.
Bataille R
Semin Hematol; 1997 Jan; 34(1 Suppl 1):23-8. PubMed ID: 9122743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
